Prosecution Insights
Last updated: November 15, 2026

Horizon Discovery Limited

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

Horizon Discovery Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 3 distinct examiners and 3 distinct art units, indicating that the current prosecution activity is spread rather than concentrated within one examination assignment.

YU, DAVID TUYANG is the busiest examiner, with 1 pending matter. Because that figure is below the portfolio's total pending activity, practitioner attention should account for examination coordination across the identified examiner and art-unit assignments.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
2
Medium (67%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other2 (67%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
YU, DAVID TUYANG 1 100.0% +0.0%
TRAN, CHRISTINA L 1 50.0% +47.0%
REGA, KYLE THOMAS 1 62.8% +42.6%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18270747 Guide RNA Designs and Complexes for Type V Cas Systems YU, DAVID TUYANG —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18011311 METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS REGA, KYLE THOMAS 41d

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18011311 METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS REGA, KYLE THOMAS 41d
18270740 Guide RNA Designs and Complexes for Tracr-less Type V Cas Systems TRAN, CHRISTINA L —

Top Art Units

Art UnitApps
1635 1
1637 1
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18270747 Guide RNA Designs and Complexes for Type V Cas Systems YU, DAVID TUYANG 1635 §102§103§112DP Final Rejection — Pending Jul 03, 2023
18270740 Guide RNA Designs and Complexes for Tracr-less Type V Cas Systems TRAN, CHRISTINA L 1637 §103§112DP Non-Final OA — Pending Jul 03, 2023
18011311 METHOD FOR PRODUCING GENETICALLY MODIFIED CELLS REGA, KYLE THOMAS 1636 §103§112 Non-Final OA 41d Pending Dec 19, 2022

Managing Horizon Discovery Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Horizon Discovery Limited have?

Horizon Discovery Limited has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most Horizon Discovery Limited applications?

David Tuyang Yu has the most, with 1 of Horizon Discovery Limited's pending office actions.

What technology area are Horizon Discovery Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month